This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Diagnosis  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(15):1528.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Measuring hemoglobin A_1c (HbA_1c) levels, a method to monitor glucose control in patients with diabetes, appears to be on the threshold of official recognition as the preferred diagnostic test for the disease.

The American Diabetes Association (ADA), along with the European Association for the Study of Diabetes and the International Diabetes Federation, will likely propose using HbA_1c as the preferred diagnostic test when revised recommendations are published later this year (American Diabetes Association. Diabetes Care. 2009;32[suppl 1]:S13-S61]).

The measurement of hemoglobin A1c levels in blood is expected to replace current methods for diagnosing patients with diabetes. (Photo credit: AJ Photo/www.sciencesource.com)

Unofficially, some primary care physicians have been using the HbA_1c measurement to diagnose diabetes because the assessments currently recommended for diagnosis, fasting plasma glucose and oral glucose tolerance tests, are viewed as burdensome to patients. HbA_1c testing was not endorsed as a diagnostic and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Role of beta-adrenergic receptor blocking agents in hypertensive diseases: personal thoughts as the controversy persists
Frohlich
Ther Adv Cardiovasc Dis 2009;3:455-464.
ABSTRACT